abstract |
A method for identifying patients with mild cognitive impairment (MCI) that may progress to Alzheimer (AD) is disclosed. This method comprises directly detecting the presence of a biochemical label, in particular human glutamine synthase, in a body fluid, preferably blood or blood product. This detection is based on an immunoassay that binds to an antibody specific for human glutamine synthase. In addition, a method for distinguishing between AD and non-AD cognitive impairment is also disclosed. |